Vancomycin

In plain language

Vancomycin is one of the oldest and most important antibiotics, used for over 60 years for serious infections by Gram-positive bacteria, especially MRSA. It is given intravenously through a slow drip.

It was found in a soil bacterium from Borneo by Eli Lilly researchers in the 1950s and approved in 1958; the name means "vanquish." Its main drawbacks are kidney toxicity and the need for blood-level monitoring, and hospitals now monitor levels closely to keep it both safe and effective.

For students

Vancomycin is a glycopeptide (about 1,449 Da) from Amycolatopsis orientalis, approved in 1958. Its heptapeptide aglycone core with cross-linked D-D amino acids and attached sugars (vancosamine and glucose) binds the D-alanine-D-alanine termini of peptidoglycan precursors, sterically blocking transglycosylation and transpeptidation, cell-wall cross-linking enzymes.

Resistance is via target modification (van operons substituting D-Ala-D-Lac), which emerged in enterococci and, more rarely, in S. aureus. Monitoring has evolved from trough-based to AUC/MIC-guided dosing (the 2020 ASHP/IDSA guidelines), reflecting nephrotoxicity risk that increases with trough levels above 15-20 mcg/mL and with concurrent piperacillin-tazobactam or aminoglycosides. It remains a first-line agent for MRSA bacteremia, and oral vancomycin (limited absorption) is a first-line therapy for Clostridioides difficile infection.

For researchers and instructors

Biochemistry. Five hydrogen bonds to the D-Ala-D-Ala dipeptide explain its potency and why a single ester-to-amide change (D-Lac) causes high-level resistance; the aglycone is the binding element while sugars tune activity and half-life.

Pharmacology. AUC/MIC target 400-600 mg-hr/L; tissue penetration is limited into lung and CSF (alternative agents preferred for MRSA pneumonia); histamine-mediated infusion reactions ("red man syndrome") are rate-related; oral formulation for C. difficile exploits negligible absorption.

Human evidence. Six decades of clinical trials and recent randomized data, including for bacteremia (versus beta-lactams in methicillin-susceptible strains, where beta-lactams win), ground its guideline position.

Teaching point. The reference case for therapeutic drug monitoring in anti-infectives, and for how resistance mechanisms directly explain structure-activity relationships.